Atlassian

Atlassian Corp's Cannon-Brookes sells 1415 shares for $98.37 each on 2026-02-05.

Macquarie Lowers Atlassian PT to $150 from $240, Maintains Outperform Rating

Wells Fargo

Wells Fargo Downgrades Atlassian to Overweight with PT Reduced to $155.

Atlassian's Q2 R&D Spend Surges to $826 Million, Shares Slide 8%

Atlassian: Oppenheimer Downgrades PT to $150, Maintains Outperform Rating

Catalyst<ul> <li>Most analysts rate TEAM Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 1 bullish) in recent technical analysis.</li> <li>Fund flows show negative trends for Small, Medium, and Large orders, indicating reduced buying pressure from smaller and mid-sized investors.</li></ul>

Key Factors

Atlassian (TEAM) reported Q2 FY26 revenue of $1.59 billion, exceeding estimates by 31%, driven by a first-ever $1.07 billion Cloud revenue quarter, up 26% YoY.Atlassian's CEO and co-founder Michael Cannon-Brookes sold 8,850 shares on February 4, 2026, for $927,000, and continued selling on February 5 and 6, 2026, alongside co-founder Scott Farquhar.Atlassian aims for 20%+ annual revenue growth through FY27, driven by AI adoption and strong enterprise sales, with annual run-rate revenue surpassing $6 billion.Atlassian's Q2 R&D spending surged to $826 million, focused on AI initiatives and the Rovo product, amid a broader AI-driven selloff impacting the tech sector.Atlassian's stock price dropped 9.82% over two days amid bearish technical signals, including a death cross and oversold RSI conditions, with volume validating the decline.

TEAM News